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SUMMARY
Most viruses are maintained by complex processes of evolution that enable them to survive but
also complicate eﬀorts to achieve their control. In this paper, we study patterns of evolution in
foot-and-mouth disease (FMD) serotype C virus isolates from Kenya, one of the few places in the
world where serotype C has been endemic and is suspected to remain. The nucleotide sequences
encoding the capsid protein VP1 from eight isolates collected between 1967 and 2004 were
analysed for patterns of sequence divergence and evolution. Very low nucleotide diversity
(p=0.0025) and remarkably little change (only ﬁve segregating sites and three amino-acid
changes) were observed in these isolates collected over a period of almost 40 years. We interpret
these results as being suggestive of re-introductions of the vaccine strain into the ﬁeld. The
implications of these results for the maintenance of serotype C FMD virus and the use of
vaccination as a control measure in Kenya are discussed.
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INTRODUCTION
Foot-and-mouth disease virus (FMDV) is an Aphtho-
virus within the family Picornaviridae. It causes a
highly contagious disease (FMD) in cloven-hoofed
animals (domestic and wild) which is the most sig-
niﬁcant constraint to international trade in livestock
and livestock products today [1]. The genome of
FMDV is a positive-sense RNA of about 8.5 kb
which encodes a polyprotein that is processed to the
four structural proteins (VP1–VP4) of the virus capsid
(only VP1–VP3 are surface exposed) plus several non-
structural proteins required for virus replication
and protein processing [2]. FMDV occurs in seven
immunologically distinct serotypes namely O, A, C,
Southern African Territories (SAT) 1–3, and Asia 1.
The seven serotypes have diﬀerent global distri-
butions with type C belonging to the Euro-Asiatic
serotypes which include O, A and Asia 1. Type C
FMDVwas ﬁrst described byWaldmann&Trautwein
[3] and has since had a limited distribution. It has been
recorded in Europe, South America, East Africa,
North Africa, Angola and Southern Asia [4]. At
present, the last reported cases of type C were in 2004
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in Brazil and Kenya [5]. In the wider East African
region, type C was last reported in Uganda in the
1970s and Ethiopia in 1983 [4, 5].
Records of serotype C outbreaks of FMD in Kenya
date back to 1957 with almost yearly occurrences
in some districts across the country which peaked in
the mid 1970s (Department of Veterinary Services,
Kenya). However, from the mid-1980s, the distri-
bution of these outbreaks has been geographically
limited to two districts in the central Rift Valley
(Baringo and Koibatek). The numbers of recorded
outbreaks of FMD, by serotype, for each year in
Kenya from 1954 to 2006 are illustrated in Figure 1.
Most of the reported outbreaks have been in cattle
with serotypes C and SAT 1 being the least prevalent
while serotypes O and SAT 2 were the most common.
In Kenya, only one type C vaccine strain (termed
K267/67 and originally isolated from Laikipia dis-
trict) produced by the Kenya Veterinary Vaccines
Production Institute (KEVEVAPI) has been used
to contain outbreaks of type C since the 1970s
(Department of Veterinary Services, Kenya records).
KEVEVAPI also produces vaccines for serotypes O
(K77/78), A (K5/80, K35/80), SAT 1 (T155/71) and
SAT 2 (K52/84).
Molecular epidemiology studies are a helpful guide
for understanding disease dynamics and for vaccine
development.Most viruses aremaintained by complex
processes of evolution that enable them to survive but
this also complicates eﬀorts aimed at achieving dis-
ease control. High levels of genetic sequence diversity
such as that reported for SAT 2 in Africa complicates
diagnosis and vaccination since the development of
suitable serotype-speciﬁc primers and vaccine strains
is diﬃcult [6]. Molecular characterization of FMDV
ﬁeld strains is useful in tracing the origin of outbreaks
and can aid in identifying possible vaccine-related
outbreaks which are genetically very close to vaccine
strains [4, 7].
Kenya is one of the few remaining suspected habi-
tats of type C FMDV globally and eﬀorts towards
progressive control of FMD will beneﬁt from estab-
lishing the current status of this serotype in this
country. Understanding the evolutionary forces shap-
ing the epidemiology of this intermittently occurring
serotype is thus desirable. This information is also
useful for decisions on control strategies and in par-
ticular the use of vaccination in endemic settings like
Kenya.
This study was undertaken to establish patterns of
evolution of type C from FMD outbreaks that oc-
curred during the period (1967–2004) using isolates
that had been stored at the Embakasi FMD labora-
tory. The VP1-coding region was used for sequence
analysis as it is one of the structural proteins forming
the virus capsid and contains important antigenic sites
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Fig. 1. Frequency of recorded outbreaks of foot-and-mouth disease by serotype in Kenya (1954–2006).
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plus the integrin receptor binding motif and is likely
to reﬂect the evolutionary dynamics of the virus
population. It has also been widely analysed pre-
viously and thus much information is available for
most serotypes.
METHODS
Virus isolates
Eight type C virus isolates were obtained from the
Embakasi FMD laboratory, Nairobi, for this study.
This laboratory is a repository of all FMD sample
materials collected in Kenya. The type C samples had
been collected over a period of almost 40 years
(1967–2004). Due to the long-term storage atx70 xC,
some of the viruses were passaged at least once in
BHK monolayer cells, one at a time, before RNA
extraction. Attempts at passaging more of the type C
samples from the bank in BHK cells were unsuccess-
ful, possibly due to deterioration as a result of unre-
liable power supplies. All of the eight virus isolates
were collected from outbreaks that occurred in the
districts of the central part of the Rift Valley province
of Kenya as shown in Figure 2. The details of the
isolates are shown in Table 1. Nine other published
type C FMDVVP1-coding sequences representing the
main topotypes were included for phylogenetic com-
parisons.
Viral RNA extraction, cDNA synthesis and
ampliﬁcation
Total RNA was extracted using the QIAamp1 Viral
RNA Mini kit (Qiagen, Germany) according to the
manufacturer’s instructions. cDNA synthesis was
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Fig. 2. Map of Kenya indicating the geographic origin of the type C foot-and-mouth disease virus isolates included in this
study.$, Sample site ; –––, district.
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performed using Ready-To-GoTM You-Prime First-
Strand Beads (GE Healthcare Life Sciences, Sweden)
with random hexamer primers (pdN6). PCR ampliﬁ-
cation of the VP1-coding region was achieved using
forward primers; C-1C536 (5k-TACAGGGATGG-
GTCTGTGTGTACC-3k) or C-1C616 (5k-AAAGA-
CTTTGAGCTCCGGCTACC-3k) with the reverse
primer FMD-2B58 (5k-GACATGTCCTCCTGCAT-
CTG-3k) [8] yielding products of y880 bp and
y800 bp, respectively. Five microlitres of template
cDNA were added to 45 ml PCR reaction mixture
containing 0.2 mM primers, 200 mM of each dNTP,
1.5 mm MgCl2 and 1 U of Amplitaq gold DNA
polymerase (Applied Biosystems, UK). Am-
pliﬁcations were performed using an Eppendorf
Mastercycler (Eppendorf, Germany) incorporating a
touchdown proﬁle as follows: enzyme activation at
95 xC for 5 min, 7 cycles of 95 xC for 15 s, touchdown
of 57 xC to 51 xC (with a decrease of 1 xC in the sub-
sequent cycle) for 1 min 30 s, 72 xC for 1 min 20 s.
This was followed by a standard PCR of 30 cycles at
95 xC for 15 s, 50 xC for 1 min 30 s, 72 xC for 1 min
20 s and a ﬁnal extension step at 72 xC for 20 min.
PCR products were examined by electrophoresis
on 2% agarose gel using ethidium bromide staining
and a molecular-weight marker WX174-RF DNA
(Amersham, Biosciences). The expected products were
puriﬁed using the QIAquick PCR puriﬁcation kit
(Qiagen). Both strands of the amplicons were cycle-
sequenced using BigDye technology on an ABI 3700
automated DNA sequencer (Applied Biosystems)
employing the forward primers used in the PCRs
and FMD-2A34 (5k-GAAGGGCCCAGGGTTGGA-
CTC-3k) [8] within the 2A region as the reverse primer.
Sequence analysis
The entire VP1-coding regions (630 nt) from the eight
Kenyan FMDV type C sequences generated in this
study and nine other reference sequences (Table 1)
were aligned using the software programs Sequencher
4.8 (Gene Codes Corporation, USA) and Geneious
v. 4.6 [9]. The model of evolution that best ﬁts the data
was selected using Akaike’s Information Criteria and
hierarchical likelihood ratio tests in MrModeltest2.2
[10] as implemented in PAUP*4b10 [11] resulting in
the selection of the HKY evolutionary model [12]
with gamma-distributed rate variation across sites
and a proportion of invariable sites (HKY+I+G) as
the preferred model.
Table 1. List of the type C viruses included in this study of which eight
sequences derived from Kenyan viruses were generated in this work while
nine were sourced from published reports
Lab. ref no.
Year of
isolation
District/
country
Accession
no. Topotype
ETH/1/71 1971 Ethiopia FJ798151 Africa
USSR/Tadjn/67 1967 Tadjikstan WRL Asia
IND/42/77 1977 India WRL Asia
BRA/Resnd/55 1955 Brazil M90381 Euro-SA
SPA/StPa/70 1970 Spain AJ133357 Euro-SA
BRA/Indl/71 1971 Brazil M90376 Euro-SA
PHI/7/84 1984 Philippines WRL Euro-SA
GER/CGC/26 1926 Germany EU553893 ?
UK/149/34 1934 UK AY593810 ?
K60/92 1992 Baringo GU451110 Africa
K15/97 1997 Koibatek GU451111 Africa
K267/67 1967 Laikipia GU451109 Africa
K14/96 1996 Koibatek GU451116 Africa
K41/97 1997 Baringo GU451112 Africa
K6/04 2004 Koibatek GU451113 Africa
K41/98 1998 Koibatek GU451114 Africa
K11/96 1996 Koibatek GU451115 Africa
WRL=from World reference laboratory sequence data website (http://www.
wrlfmd.org/fmd_genotyping/prototypes.htm).
?, Not assigned.
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Sequence characteristics
The level of nucleotide sequence divergence was in-
ferred using DnaSP v5 [13] to determine values of
nucleotide diversity, pi (p), [14] and the number of
segregating sites. The amino-acid substitutions pre-
dicted from the sequences were identiﬁed using
MEGA4 [15].
Phylogenetic relationships
Phylogenetic relationships between the type C virus
isolates were determined using MrBayes [16] as-
suming an HKY+I+G model. The Markov Chain
Monte Carlo search was run with three chains for
500 000 generations ; with trees being sampled every
100 generations (the ﬁrst 500 trees were discarded as
‘burn-in’).
RESULTS
Sequence characteristics
A very low level of nucleotide diversity (values of
p=0.0025) was observed in the eight Kenyan FMDV
type C VP1-coding sequences. There were only ﬁve
segregating sites at nucleotide positions 309, 327, 331,
335 and 435. These substitutions encoded only three
amino-acid changeswithin theVP1protein (at residues
109, 111, 112) resulting from the non-synonymous
nucleotide changes at positions 327, 331 and 335 in
the Kenyan virus isolates (Fig. 3). While the other
Kenyan type C virus isolates were invariant at amino-
acid residues 109 and 112, the isolate K15/97 had two
substitutions [glutamine (Q) and arginine (R) in place
of histidine (H109) and proline (P112), respectively].
However, the K15/97 isolate, together with isolates
K267/67 and K14/96, had a glycine (G) residue at
position 111, like the reference topotypes, while the
other Kenyan virus isolates had an arginine (R). It
should be noted that the ‘RGD’ motif (residues
144–146), required for binding to the integrin receptor
[17, 18], was completely conserved in the Kenyan
serotype C virus isolates.
Phylogenetic relationships
The Kenyan FMDV type C virus isolates are very
closely related to each other within the African topo-
type (Fig. 4). They belong to a single clade on the
phylogenetic tree. The vaccine strain K267/67 is
identical to K14/96 in this region while the others
(K11/96, K41/97, K41/98, K6/04) are identical to
K60/92. This grouping reﬂects the identity of resi-
due 111; which is a glycine (G) in the former and
arginine (R) in the latter strains, respectively. The
other nucleotide changes (positions 309, 327, 335,
435) observed were all in isolate K15/97.
Fig. 3. VP1 coding region and amino-acid sequence comparison between the serotype C sequences analysed in this study.
Only variable sites indicating changes in the Kenyan sequences are shown with nucleotide and amino-acid positions marked
above and below the sequences, respectively. Variant amino acids (aa) are indicated in bold. ‘ . ’ Indicates a nucleotide site
identical to that of the sequence GER/CGC/26 (Germany, 1926) and ‘–’ denotes a missing nucleotide.
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DISCUSSION
There has been very little change in the sequence of the
VP1-coding region over a period of almost 40 years in
the Kenyan type C FMDV isolates. Moreover, the
vaccine strain (K267/67) that has been used to contain
type C outbreaks is genetically closely related to each
of the ﬁeld strains. This lack of signiﬁcant variation in
viruses isolated over a long period of time is incon-
sistent with the expected levels of divergence given the
rapid evolution of FMD viruses previously reported
(e.g. [19–22]). FMDV serotypes are known to evolve
rapidly resulting in a high lineage turnover [23].
Diﬀerences exist in the selection forces shaping the
evolution of the serotypes with, for example, type C
and SAT 3 major antigenic regions reported to be
under no positive Darwinian selection when VP1-
coding sequences were analysed [24]. However, the
low level of sequence divergence observed in this
study is comparable to that observed in C1 subtype
strains from Europe, which showed very little change
from 1953 to 1989 [4]. The absence of signiﬁcant se-
quence divergence in type C strains has also been
reported in India [25]. The apparently static evolution
in the European subtype C1 strains was attributed
to multiple re-introductions of vaccine strains into
the ﬁeld through laboratory escapes or improperly
inactivated vaccines. Many FMD outbreaks in
Europe in the past have been attributed to improperly
inactivated vaccines when formaldehyde was used [7].
For Kenya, available records at KEVEVAPI indicate
that by the early 1980s, formaldehyde had been aban-
doned and binary ethyleneimine (BEI) was in use for
virus inactivation during vaccine production as rec-
ommended in Doel [26]. Type C vaccine has been
distributed to the districts reporting type C outbreaks
solely through the Directorate of Veterinary Services.
The practice has been to apply ring vaccination to
contain the outbreaks once reported and this applies
to all the isolates in this study, i.e. vaccine was applied
following the outbreak. Type C vaccine use peaked in
the 1970s and early 1980s when the number of re-
ported outbreaks was high (up to about 50 outbreaks
a year aﬀecting many districts) but then fell in the
1990s when only a few districts were aﬀected. Kajiado
district in the southern Rift Valley received the high-
est number of type C FMDV vaccine doses in 1973
(n=105 800 doses). From the 1990s up to the last
reported outbreak of type C in 2004, Baringo and
Koibatek were the only districts that were supplied
with type C vaccine to ring vaccinate and control
respective outbreaks.
In a preliminary study, Roeder & Knowles [5]
reported a close relationship between some Kenyan
Africa
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K41/97 
K6/04 
K41/98 
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Fig. 4. Bayesian inference tree indicating the phylogenetic relationships between serotype C foot-and-mouth disease virus
isolates. The three topotypes (Africa, Asia and Europe-South America) are indicated. Posterior probabilities >50% for
nodes are shown.
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type C strains and the vaccine strain K267/67 and
suggested that this could be due to re-introductions of
the vaccine strain into the ﬁeld. They recommended
the suspension of the use of the vaccine. Additionally,
Kenyan ﬁeld isolates of type C were observed to be
antigenically closely related to the vaccine strain
(Embakasi FMD laboratory records).
In the Kenyan situation, it is highly improbable
that direct laboratory escape of the virus could be a
source of these particular outbreaks as the concerned
districts are geographically distant (>200 km) from
Nairobi where the laboratory is located. Previous
laboratory escapes of FMD viruses have been re-
ported to occur near laboratories as was the case in
the UK in 2007 [27]. Epidemiological information
on the Kenyan outbreaks obtained by the veterinary
department on the likely source and history of each
outbreak also excluded possible escapes from the
laboratory based on the fact that they occurred in
districts far from Nairobi and no obvious trans-
mission method, such as through laboratory person-
nel or visitors, could be found.
A possible explanation for these results is im-
properly inactivated vaccines as a probable source of
ﬁeld re-introductions which is consistent with the
conclusions from Roeder & Knowles [5] and similar
reports in Europe [7], although the use of BEI early in
the history of vaccine production at KEVEVAPI and
the fact that vaccine was only used after the outbreak
was reported makes this inference uncertain. High
sequence similarity could also result from cross-
contamination of the samples, for example during cell
culture passage. Such a possibility is also unlikely in
this study since the isolates were passaged at diﬀerent
times and incorporated negative controls of un-
infected monolayer cells incubated in parallel and
checked for lack of any cytopathic eﬀects in strict
adherence to good laboratory practice. The sugges-
tion of improperly inactivated vaccines, although
not unequivocally proven, highlights the importance
of strengthening the availability of laboratory di-
agnostic capability at national FMD laboratories.
However, to our knowledge, neither a deﬁnitive con-
ﬁrmation of vaccine-related outbreaks nor its possible
epidemiological impact in Kenya has been reported.
Although the conservative magnitude of change as
well as the close similarity to the vaccine strain ob-
served in this study for type C suggests that type C
outbreaks are probably of vaccine origin, we found
little evidence of vaccine strain re-introductions for
the other serotypes in Kenya (unpublished results by
the authors). Instead we observe a high rate of virus
turnover for the other Kenyan FMDV serotypes as
exempliﬁed by as many as six (SAT 2), four (type A)
and three (type O) changes in vaccine strains over a
similar period. This is despite the vaccine production
procedure being the same for all the serotypes and
the other serotype vaccines being used in much
larger quantities and over a similar time period as
the type C vaccine. Similarly, no outbreaks have
been associated with vaccine inoculation during
potency experiments. However, on the World Ref-
erence Laboratory for FMD website (http://www.
wrlfmd.org/fmd_genotyping/africa/ken.htm) there
appears to be evidence of ﬁeld viruses being isolated
sporadically which have very close genetic relation-
ships to the other Kenyan vaccine strains.
The suggestion of probable vaccine strain re-
introductions of this serotype in Kenya has im-
plications for the control of the disease through
vaccination. It may therefore be necessary to obtain
deﬁnitive evidence for the possible linkage of the
use of vaccines in the maintenance of serotype C
FMD in Kenya. The association of vaccine usage with
outbreaks poses a dilemma for the veterinary auth-
orities in the country who have to decide on whether
to continue maintaining expensive vaccine stocks for
a seemingly disappearing serotype.
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